|PDI, Inc. Subsidiary Interpace Diagnostics Enters Molecular Diagnostics Market with Thyroid and Pancreatic Cancer Test Portfolio Acquisition|
MiRInform Thyroid is a diagnostic assay comprised of 17 markers recommended by the
MiRInform Pancreas is a market-ready microRNA test expected to launch in the first half of 2015. This product has demonstrated significant clinical utility in detecting cancer in solid pancreatic tumors in a prospective clinical study.
This transaction includes the miRInform Thyroid and Pancreas tests, intellectual property related to these and other tests in development for thyroid cancer, and an extensive 5,000 plus tissue sample biobank to support life cycle management efforts. Terms of the transaction include
"Today's portfolio acquisition is a pivotal step in PDI's strategy to leverage our extensive healthcare go-to-market experience and infrastructure in the higher margin, high-growth market of molecular diagnostics," said Nancy Lurker, CEO,
Twenty to thirty percent of thyroid biopsy samples obtained through fine needle aspiration (FNA) are considered indeterminate following cytological analysis.[ii] MiRInform Thyroid is used by pathologists and endocrinologists to improve preoperative diagnostic accuracy and aid in the characterization of malignancy for malignant and indeterminate biopsied samples through the analysis of 17 validated genetic alterations.
MiRInform Pancreas is expected to aid physicians in differentiating between the benign condition of chronic pancreatitis and pancreatic cancer in solid masses. Pancreatic cancer determination is often difficult with a significant number of indeterminate diagnoses and up to a 30 percent false negative rate for FNA biopsies.
About miRInform Thyroid
About miRInform Pancreas
"To better focus on our rapidly growing molecular diagnostic products and translational diagnostic services businesses, Asuragen decided to divest the miRInform assets," said
[i] Beaudenon-Huibregtse S, et al. Thyroid. [published online ahead of print
Media: Caren Begun, Green Room Communications, (856) 424-2023, Caren@GreenRoomPR.com; Investors: Asher S. Dewhurst, Westwicke Partners, LLC, (443) 213-0503, Asher.Dewhurst@westwicke.com